[Comparison of the effectiveness of moxonidine and prestarium in postmenopausal women with mild and moderate arterial hypertension].
The subjects of this randomized comparative study were 36 postmenopausal women aged 53.7 +/- 1.4 years, suffering from arterial hypertension (AH). The aim was to evaluate the clinical effectiveness of moxonidine, an imidazoline receptor agonist, and prestarium, an angiotensin converting enzyme (ACE) inhibitor, and their effects on target organs and lipid metabolism. The groups were comparable in age, sex, AH duration, as well as office systolic and diastolic arterial pressure. The study demonstrated comparable hypotensive effects of both pharmaceuticals, although moxonidine had an effect on target organs (left ventricular myocardial hypertrophy). After 6 months of treatment moxonidine significantly lowered left ventricular myocardial mass (12.7% on the average, p < 0.05). The study also revealed a positive effect of moxonidine on lipid exchange variables.
Bakhshaliev
A B
AB
Sabzalieva
G M
GM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use*; D017698:Postmenopause; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016276:Ventricular Function / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007093:Imidazoles; C043482:moxonidine; D020913:Perindopril